|
|
| Elan Named on Forbes Global Annual A-List |
DUBLIN, Ireland, Jan. 8 /PRNewswire/ -- Elan Corporation, plc (NYSE: ELN) ("Elan") today announced that it has been listed as the "A+" Healthcare company on the Forbes Global A-List of the "400 Best Companies". In its annual A-List, Forbes Global magazine names "the biggest, the most profitable and the most promising" companies by sector, then selects one "A+" company as the standout in each sector. In an accompanying profile which appears in the January 8 edition, Forbes Global notes that for the past five years, Elan's annual revenues have grown by an average of 49 percent; that Elan is the world's market leader in drug delivery technology; and that Elan is transforming into an integrated pharmaceutical company by developing drugs in neurology, oncology, and pain management. The profile also notes that Elan is a leader in Alzheimer's disease research. "On behalf of Elan, I am pleased that Forbes Global has selected our company as the 'A+' healthcare company on their "A List" of Healthcare companies," said Donal J. Geaney, Elan's chairman and chief executive officer. "This achievement is particularly gratifying and reflects the underlying strength of Elan's pharmaceutical and drug delivery businesses. This is an honor shared by every member of the Elan organization." Elan Corporation, plc is a leading worldwide specialty pharmaceutical and drug delivery company headquartered in Ireland, with its principal research, development, manufacturing and marketing facilities located in Ireland, the United States and Israel. Elan is focused on the discovery, development and marketing of therapeutic products and services in neurology, pain management andoncology, and on the development and commercialization of products using its extensive range of proprietary drug delivery technologies. Elan shares trade on the New York, London and Dublin Stock Exchanges.SOURCE Elan Corporation, plc
back to topRelated links:
Company News On-Call:
800-758-5804, ext. 231593
CONTACT:
Max Gershenoff of Elan, 212-407-5740 or
800-252-3526
